share_log

Arcutis Biotherapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

Arcutis Biotherapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

Arcutis Biotherapeutics | 144:拟议出售证券
美股SEC公告 ·  2024/11/05 05:44

Moomoo AI 已提取核心信息

Arcutis Biotherapeutics, Inc. officer Todd Franklin Watanabe is set to sell 13,871 shares of common stock on November 4, 2024. The shares, valued at an aggregate market value of $120,459, were acquired by Watanabe on November 1, 2024, through a restricted stock vest from Arcutis Biotherapeutics. This transaction follows a period where no other securities were sold by Watanabe in the past three months, as per the provided transaction history.
Arcutis Biotherapeutics, Inc. officer Todd Franklin Watanabe is set to sell 13,871 shares of common stock on November 4, 2024. The shares, valued at an aggregate market value of $120,459, were acquired by Watanabe on November 1, 2024, through a restricted stock vest from Arcutis Biotherapeutics. This transaction follows a period where no other securities were sold by Watanabe in the past three months, as per the provided transaction history.
arcutis biotherapeutics,Inc. 官员 Todd Franklin Watanabe 计划在2024年11月4日卖出13,871股普通股。这些股票市值总计120,459美元,是Watanabe于2024年11月1日通过Arcutis Biotherapeutics的限制股票归属权获得的。根据提供的交易历史,此次交易是在过去三个月中Watanabe没有出售其他证券的时期之后进行的。
arcutis biotherapeutics,Inc. 官员 Todd Franklin Watanabe 计划在2024年11月4日卖出13,871股普通股。这些股票市值总计120,459美元,是Watanabe于2024年11月1日通过Arcutis Biotherapeutics的限制股票归属权获得的。根据提供的交易历史,此次交易是在过去三个月中Watanabe没有出售其他证券的时期之后进行的。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息